Business Segments GSK plc

Equities

Market Closed - London S.E. Other stock markets 19:35:01 06/03/2026 +03			5-day change	1st Jan Change
2,038.00 ^GBX	-1.83%		-7.41%	+11.70%

03-05	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI
03-05	GSK outgoing CEO Emma Walmsley's 2025 total remuneration was 15.7 mln pounds vs 10.6 mln pounds in 2024 - annual report	RE

Breakdown by Business Segment (GBP)

Fiscal Period: December	2021	2022	2023	2024	2025
Biological Products
Commercial Operations	-	29.32B	30.33B	31.38B	-
D&A	-	829M	893M	906M	-
Operating Income	-	13.59B	14.66B	15.34B	-
Corporate and Other Unallocated Turnover	-	-	-	-	-
Operating Income	-370M	-379M	-263M	-342M	-
D&A	54M	112M	110M	74M	-
D&A	802M	739M	719M	1B	-
Dental Care Products
Consumer Healthcare	9.61B	-	-	-	-
D&A	226M	-	-	-	-
Operating Income	2.24B	-	-	-	-
Pharmaceutical Research and Development
D&A	325M	467M	572M	569M	-
Operating Income	-3.49B	-5.06B	-5.61B	-5.84B	-
Pharmaceutical Products
Vaccines	6.78B	-	-	-	-
D&A	416M	-	-	-	-
Operating Income	2.26B	-	-	-	-
Pharmaceuticals	17.73B	-	-	-	-
D&A	553M	-	-	-	-
Operating Income	8.17B	-	-	-	-

Geographical breakdown of sales (GBP)

Fiscal Period: December	2021	2022	2023	2024	2025
United Kingdom (UK)	975M	695M	693M	708M	-
Total Assets	6.62B	5.13B	6.46B	7.8B	-
Operating Income	-	-	-	-	-
Total Assets	5.06B	5.42B	5.34B	5.38B	-
Total Assets	6.55B	34M	-	-	-
Inter-Segment Turnover	-	-	-	-	-
International	18.05B	14.09B	13.82B	14.28B	-
Total Assets	15.39B	6.56B	6.61B	5.59B	-
Operating Income	-	-	-	-	-
United States (US)	15.09B	14.54B	15.82B	16.38B	-
Total Assets	17.85B	14.02B	13.28B	13.98B	-
Operating Income	-	-	-	-	-